Brainsway (BWAY) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.07
- Estimate
- $0.07
- Surprise
- -4.5%
- Score today
- 6.3/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Brainsway (BWAY) reported diluted EPS of $0.07, in line with the $0.07 estimate.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BWAY Hold at 6.3/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -4.5% surprise compares with a +39.1% four-quarter average. Next scheduled report: 2026-11-10.
What supports the rating
- Strong growth profile
- Wide economic moat
What argues against it
- Thin upside margin: 7.3%
- Negative momentum
- Momentum score 2.4/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $14.74
- Price target
- $15.81
- Stop
- $13.72
- Upside to target
- +7.3%
- Reward-to-risk
- 0.6:1
The stock trades at 64.1× trailing but 30.3× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
BWAY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $592.4M
- P/E (fwd)
- 30.3
- P/E (ttm)
- 64.1
- 52-week range
- $7.13–$17.40
- Off 52-week high
- 15.3%
- RSI (14)
- 42
- Volume vs avg
- 0.32×
- Score today
- 6.3/10